Stephen S. Gottlieb, MD

Dr. Gottlieb is well known for his work related to heart failure and cardiac amyloidosis. He has extensive experience treating patients with amyloidosis—a rare disease that occurs when a protein called amyloid builds up in organs—and has been working for over a decade to develop drugs for the disease. He is now investigating various types of new drugs with the potential to reverse the disease.

Dr. Gottlieb’s research centers on the physiology and therapy of congestive heart failure. This includes a particular interest in neurohormonal activation and renal function in CHF patients. Having studied the impact of adenosine antagonists and other medications and interventions on renal function and the physiology of renal function in heart failure patients, he is interested in the interaction of heart failure and renal dysfunction. He investigates new therapies and is currently working on new inotropes, vasodilators and devices. He was the United States' principal investigator for the groundbreaking MERIT-HF evaluation of beta blockers.

Dr. Gottlieb trained at Brown University (Providence, Rhode Island), the University of Chicago (Chicago, Illinois) and Mount Sinai Hospital in New York City, New York. He has been at University of Maryland School of Medicine since 1988 and is currently professor of medicine and director of the Clinical Research Program in Cardiology.

Dr. Gottlieb has published about the interaction of depression and heart failure. In addition, he has investigated the effects of home telemonitoring, sleep abnormalities and genetic polymorphisms in heart failure patients.